Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites.

The New England journal of medicine - 27 May 2004

Muir Andrew J, Bornstein Jeffrey D, Killenberg Paul G

Abstract excerpt

BACKGROUND: Several small studies have reported a lower response rate to interferon alfa among black patients with chronic hepatitis C infection than among white patients. The increased prevalence of infection with hepatitis C virus (HCV) genotype 1, which has a lower response rate than other genotypes, has been suggested as the cause. METHODS: We treated 100 black patients and 100 non-Hispanic white patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Black or African American
Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis C, Chronic

Share to Interferon-alpha

Share to Interferon alpha-2

Share to Polyethylene Glycols

Share to Ribavirin

Share to Socioeconomic Factors

Source

Identifiers

PMID: 15163776
DOI: 10.1056/NEJMoa032502

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites.PMID 15163776Read ↗

Black patients with chronic hepatitis C have a lower sustained viral response rate than non-Blacks with genotype 1, but the same with genotypes 2/3, and this is not explained by more frequent dose reductions of interferon and ribavirin*.Semantic proximity Read ↗

Daclatasvir and Peginterferon/Ribavirin for Black/African-American and Latino Patients with HCV infection.Semantic proximity Read ↗

Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1.Semantic proximity Read ↗

Elbasvir/grazoprevir in black adults with hepatitis C virus infection: a pooled analysis of phase 2/3 clinical trials.Semantic proximity Read ↗

Boceprevir for untreated chronic HCV genotype 1 infection.Semantic proximity Read ↗

Equally poor outcomes to pegylated interferon-based therapy in African Americans and Hispanics with chronic hepatitis C infection.Semantic proximity Read ↗

Vitamin D and the racial difference in the genotype 1 chronic hepatitis C treatment response.Semantic proximity Read ↗

Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C.Semantic proximity Read ↗

Response to therapy with pegylated interferon and ribavirin for chronic hepatitis C in hispanics compared to non-Hispanic whites.Semantic proximity Read ↗

Hepatitis C-positive Black patients develop hepatocellular carcinoma at earlier stages of liver disease and present with a more aggressive phenotype.Semantic proximity Read ↗

Sustained virologic response rates with telaprevir-based therapy in treatment-naive patients evaluated by race or ethnicity.Semantic proximity Read ↗

Sustained virological response rate to pegylated interferon plus ribavirin for chronic hepatitis C in African Americans: results in treatment-naïve patients in a university liver clinic.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.